IP Library › Granted Patent US 12,448,451
Granted Patent B2
US 12,448,451 · App. 17/848,983 · Granted Oct 21, 2025

Anti-CTLA-4 antibody and use thereof

Inventors: Hitoshi Katada (Singapore, SG); Kanako Tatsumi (Shizuoka, JP); Yutaka Matsuda (Tokyo, JP); Shun Shimizu (Shizuoka, JP); Masaki Kamimura (Kanagawa, JP); Yasunori Komori (Shizuoka, JP); Yuji Hori (Shizuoka, JP); Tomoyuki Igawa (Tokyo, JP); Hiroki Kawauchi (Kanagawa, JP); Hiroki Hayashi (Kanagawa, JP); Hiroaki Susumu (Kanagawa, JP); Shimon Sakaguchi (Osaka, JP)
Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA; OSAKA UNIVERSITY
C07K16/2818A61K2039/505C07K2317/52C07K2317/56C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,448,451
App. No.
17/848,983
Granted
Oct 21, 2025
Kind
B2
Abstract

The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Pc region and methods of producing and using the polypeptides.

Claims (59)

1. A method of treating an individual having a tumor comprising administering to the individual an effective amount of an anti-CTLA-4 antibody comprising:

(A) a variable region comprising

(i) a variable region comprising the VH sequence of SEQ ID NO: 98 and the VL sequence of SEQ ID NO: 99;

(ii) a variable region comprising the VH sequence of SEQ ID NO: 83 and the VL sequence of SEQ ID NO: 88;

(iii) a variable region comprising the VH sequence of SEQ ID NO: 83 and the VL sequence of SEQ ID NO: 89;

(iv) a variable region comprising the VH sequence of SEQ ID NO: 83 and the VL sequence of SEQ ID NO: 90;

(v) a variable region comprising the VH sequence of SEQ ID NO: 83 and the VL sequence of SEQ ID NO: 91;

(vi) a variable region comprising the VH sequence of SEQ ID NO: 83 and the VL sequence of SEQ ID NO: 92;

(vii) a variable region comprising the VH sequence of SEQ ID NO: 83 and the VL sequence of SEQ ID NO: 93;

(viii) a variable region comprising the VH sequence of SEQ ID NO: 83 and the VL sequence of SEQ ID NO: 94;

(ix) a variable region comprising the VH sequence of SEQ ID NO: 83 and the VL sequence of SEQ ID NO: 97;

(x) a variable region comprising the VH sequence of SEQ ID NO: 83 and the VL sequence of SEQ ID NO: 95;

(xi) a variable region comprising the VH sequence of SEQ ID NO: 84 and the VL sequence of SEQ ID NO: 97;

(xii) a variable region comprising the VH sequence of SEQ ID NO: 85 and the VL sequence of SEQ ID NO: 97;

(xiii) a variable region comprising the VH sequence of SEQ ID NO: 86 and the VL sequence of SEQ ID NO: 97;

(xiv) a variable region comprising the VH sequence of SEQ ID NO: 86 and the VL sequence of SEQ ID NO: 134;

(xv) a variable region comprising the VH sequence of SEQ ID NO: 136 and the VL sequence of SEQ ID NO: 97;

(xvi) a variable region comprising the VH sequence of SEQ ID NO: 135 and the VL sequence of SEQ ID NO: 97;

(xvii) a variable region comprising the VH sequence of SEQ ID NO: 136 and the VL sequence of SEQ ID NO: 95;

(xviii) a variable region comprising the VH sequence of SEQ ID NO: 137 and the VL sequence of SEQ ID NO: 97;

(xix) a variable region comprising the VH sequence of SEQ ID NO: 138 and the VL sequence of SEQ ID NO: 97;

(xx) a variable region comprising the VH sequence of SEQ ID NO: 138 and the VL sequence of SEQ ID NO: 144;

(xxi) a variable region comprising the VH sequence of SEQ ID NO: 138 and the VL sequence of SEQ ID NO: 145;

(xxii) a variable region comprising the VH sequence of SEQ ID NO: 138 and the VL sequence of SEQ ID NO: 146;

(xxiii) a variable region comprising the VH sequence of SEQ ID NO: 139 and the VL sequence of SEQ ID NO: 146;

(xxiv) a variable region comprising the VH sequence of SEQ ID NO: 140 and the VL sequence of SEQ ID NO: 146;

(xxv) a variable region comprising the VH sequence of SEQ ID NO: 141 and the VL sequence of SEQ ID NO: 146;

(xxvi) a variable region comprising the VH sequence of SEQ ID NO: 140 and the VL sequence of SEQ ID NO: 147;

(xxvii) a variable region comprising the VH sequence of SEQ ID NO: 141 and the VL sequence of SEQ ID NO: 147;

(xxviii) a variable region comprising the VH sequence of SEQ ID NO: 140 and the VL sequence of SEQ ID NO: 148;

(xxix) a variable region comprising the VH sequence of SEQ ID NO: 141 and the VL sequence of SEQ ID NO: 148;

(xxx) a variable region comprising the VH sequence of SEQ ID NO: 136 and the VL sequence of SEQ ID NO: 149;

(xxxi) a first heavy chain variable region comprising the VH sequence of SEQ ID NO: 140 and a first light chain variable region comprising the VL sequence of SEQ ID NO: 146, and a second heavy chain variable region comprising the VH sequence of SEQ ID NO: 141 and a second light chain variable region comprising the VL sequence of SEQ ID NO: 146; or

(xxxii) a first heavy chain variable region comprising the VH sequence of SEQ ID NO: 140 and a first light chain variable region comprising the VL sequence of SEQ ID NO: 147, and a second heavy chain variable region comprising the VH sequence of SEQ ID NO: 141 and a second light chain variable region comprising the VL sequence of SEQ ID NO: 147; and

(B) a heavy chain constant region domain comprising:

(i) a first polypeptide of SEQ ID NO: 383 and a second polypeptide of SEQ ID NO: 384, or

(ii) a first polypeptide of SEQ ID NO: 376 and a second polypeptide of SEQ ID NO: 377, wherein the tumor is selected from the group consisting of lung cancer, large intestine cancer, colon cancer, breast cancer, liver cancer, pancreatic cancer, renal cancer, bladder cancer, head and neck cancer, and melanoma.

2. A method of treating an individual having a tumor comprising administering to the individual an effective amount of an anti-CTLA-4 antibody comprising:

(1) a first heavy chain polypeptide of SEQ ID NO: 385, a second heavy chain polypeptide of SEQ ID NO: 386, and a light chain polypeptide of SEQ ID NO: 161; or

(2) a first heavy chain polypeptide of SEQ ID NO: 368, a second heavy chain polypeptide of SEQ ID NO: 369, and a light chain polypeptide of SEQ ID NO: 161,

wherein the tumor is selected from the group consisting of lung cancer, large intestine cancer, colon cancer, breast cancer, liver cancer, pancreatic cancer, renal cancer, bladder cancer, head and neck cancer, and melanoma.

3. The method of claim 1 , wherein the administered anti-CTLA-4 antibody comprises a variable region comprising the VH sequence of SEQ ID NO: 140 or SEQ ID NO: 141 and the VL sequence of SEQ ID NO: 146.

4. The method of claim 1 , wherein the administered anti-CTLA-4 antibody comprises a variable region comprising the VH sequence of SEQ ID NO: 140 or SEQ ID NO:141 and the VL sequence of SEQ ID NO: 147.

5. The method of claim 1 , wherein the administered anti-CTLA-4 antibody comprises a first heavy chain variable region comprising the VH sequence of SEQ ID NO: 140 and a first light chain variable region comprising the VL sequence of SEQ ID NO: 146, and a second heavy chain variable region comprising the VH sequence of SEQ ID NO: 141 and a second light chain variable region comprising the VL sequence of SEQ ID NO: 146.

6. The method of claim 1 , wherein the administered anti-CTLA-4 antibody comprises a first heavy chain variable region comprising the VH sequence of SEQ ID NO: 140 and a first light chain variable region comprising the VL sequence of SEQ ID NO: 147, and a second heavy chain variable region comprising the VH sequence of SEQ ID NO: 141 and a second light chain variable region comprising the VL sequence of SEQ ID NO: 147.

7. The method of claim 1 , wherein the administered anti-CTLA-4 antibody comprises a heavy chain constant region domain comprising a first polypeptide of SEQ ID NO: 383 and a second polypeptide of SEQ ID NO: 384.

8. The method of claim 3 , wherein the administered anti-CTLA-4 antibody comprises a heavy chain constant region domain comprising a first polypeptide of SEQ ID NO: 383 and a second polypeptide of SEQ ID NO: 384.

9. The method of claim 4 , wherein the administered anti-CTLA-4 antibody comprises a heavy chain constant region domain comprising a first polypeptide of SEQ ID NO: 383 and a second polypeptide of SEQ ID NO: 384.

10. The method of claim 5 , wherein the administered anti-CTLA-4 antibody comprises a heavy chain constant region domain comprising a first polypeptide of SEQ ID NO: 383 and a second polypeptide of SEQ ID NO: 384.

11. The method of claim 6 , wherein the administered anti-CTLA-4 antibody comprises a heavy chain constant region domain comprising a first polypeptide of SEQ ID NO: 383 and a second polypeptide of SEQ ID NO: 384.

12. The method of claim 1 , wherein the administered anti-CTLA-4 antibody comprises a heavy chain constant region domain comprising a first polypeptide of SEQ ID NO: 376 and a second polypeptide of SEQ ID NO: 377.

13. The method of claim 3 , wherein the administered anti-CTLA-4 antibody comprises a heavy chain constant region domain comprising a first polypeptide of SEQ ID NO: 376 and a second polypeptide of SEQ ID NO: 377.

14. The method of claim 4 , wherein the administered anti-CTLA-4 antibody comprises a heavy chain constant region domain comprising a first polypeptide of SEQ ID NO: 376 and a second polypeptide of SEQ ID NO: 377.

15. The method of claim 5 , wherein the administered anti-CTLA-4 antibody comprises a heavy chain constant region domain comprising a first polypeptide of SEQ ID NO: 376 and a second polypeptide of SEQ ID NO: 377.

16. The method of claim 6 , wherein the administered anti-CTLA-4 antibody comprises a heavy chain constant region domain comprising a first polypeptide of SEQ ID NO: 376 and a second polypeptide of SEQ ID NO: 377.

17. The method of claim 2 , wherein the administered anti-CTLA-4 antibody comprises a first heavy chain polypeptide of SEQ ID NO: 385, a second heavy chain polypeptide of SEQ ID NO: 386, and a light chain polypeptide of SEQ ID NO: 161.

18. The method of claim 2 , wherein the administered anti-CTLA-4 antibody comprises a first heavy chain polypeptide of SEQ ID NO: 368, a second heavy chain polypeptide of SEQ ID NO: 369, and a light chain polypeptide of SEQ ID NO: 161.

19. The method of claim 1 , wherein the tumor is selected from the group consisting of lung cancer, large intestine cancer, colon cancer, head and neck cancer, and melanoma.

20. The method of claim 2 , wherein the tumor is selected from the group consisting of lung cancer, large intestine cancer, colon cancer, head and neck cancer, and melanoma.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2022
From: CHUGAI SEIYAKU KABUSHIKI KAISHA
To: CHUGAI SEIYAKU KABUSHIKI KAISHA; OSAKA UNIVERSITY
Reel/Frame 060947/0584 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2022
From: KATADA, HITOSHI; TATSUMI, KANAKO; MATSUDA, YUTAKA; SHIMIZU, SHUN; KAMIMURA, MASAKI; KOMORI, YASUNORI; HORI, YUJI; IGAWA, TOMOYUKI; KAWAUCHI, HIROKI; HAYASHI, HIROKI; SUSUMU, HIROAKI
To: CHUGAI SEIYAKU KABUSHIKI KAISHA
Reel/Frame 060861/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2022
From: OSAKA UNIVERSITY
To: CHUGAI SEIYAKU KABUSHIKI KAISHA
Reel/Frame 060861/0607 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2022
From: SAKAGUCHI, SHIMON
To: OSAKA UNIVERSITY
Reel/Frame 060861/0616 →
Priority Claims (2)
JP 2021-105804 · Jun 25, 2021 · national
JP 2021-105823 · Jun 25, 2021 · national
Continuity (2)
Related Publication 20230020377A1 · Jan 19, 2023
Related Publication 20240002510A2 · Jan 4, 2024
References Cited (341)
US 6737056B1 · Presta · 2004 [cited by applicant]
US 7632497B2 · Stavenhagen et al. · 2009 [cited by applicant]
US 7951917B1 · Arathoon et al. · 2011 [cited by applicant]
US 8188231B2 · Lazar et al. · 2012 [cited by applicant]
US 8524867B2 · Bernett et al. · 2013 [cited by applicant]
US 8586713B2 · Davis et al. · 2013 [cited by applicant]
US 8592562B2 · Kannan et al. · 2013 [cited by applicant]
US 9200060B2 · Kannan et al. · 2015 [cited by applicant]
US 9228017B2 · Igawa et al. · 2016 [cited by applicant]
US 9562109B2 · Von Kreudenstein et al. · 2017 [cited by applicant]
US 9670269B2 · Igawa et al. · 2017 [cited by applicant]
US 9688762B2 · Igawa et al. · 2017 [cited by applicant]
US 9890218B2 · Mimoto et al. · 2018 [cited by applicant]
US 10011858B2 · Igawa et al. · 2018 [cited by applicant]
US 10066018B2 · Igawa et al. · 2018 [cited by applicant]
US 10196445B1 · Engelhardt et al. · 2019 [cited by applicant]
US 10251945B2 · Engelhardt et al. · 2019 [cited by applicant]
US 10253091B2 · Igawa et al. · 2019 [cited by applicant]
US 10766960B2 · Igawa et al. · 2020 [cited by applicant]
US 10934344B2 · Igawa et al. · 2021 [cited by applicant]
US 10961530B2 · Igawa et al. · 2021 [cited by applicant]
US 11013802B2 · Van Dijk et al. · 2021 [cited by applicant]
US 11124576B2 · Igawa et al. · 2021 [cited by applicant]
US 11142563B2 · Igawa et al. · 2021 [cited by applicant]
US 11168344B2 · Igawa et al. · 2021 [cited by applicant]
US 11332533B2 · Igawa et al. · 2022 [cited by applicant]
US 11359016B2 · Lou et al. · 2022 [cited by applicant]
US 11673947B2 · Igawa et al. · 2023 [cited by applicant]
US 11912989B2 · Igawa et al. · 2024 [cited by applicant]
US 20060024298A1 · Lazar et al. · 2006 [cited by applicant]
US 20060134709A1 · Stavenhagen et al. · 2006 [cited by applicant]
US 20060275283A1 · Van Vlijmen et al. · 2006 [cited by applicant]
US 20080051563A1 · Lazar et al. · 2008 [cited by applicant]
US 20090053211A9 · Lazar et al. · 2009 [cited by applicant]
US 20090263392A1 · Igawa et al. · 2009 [cited by applicant]
US 20100015133A1 · Igawa et al. · 2010 [cited by applicant]
US 20100272723A1 · Bernett et al. · 2010 [cited by applicant]
US 20100286374A1 · Kannan et al. · 2010 [cited by applicant]
US 20100298542A1 · Igawa et al. · 2010 [cited by applicant]
US 20100331527A1 · Davis et al. · 2010 [cited by applicant]
US 20110287009A1 · Scheer et al. · 2011 [cited by applicant]
US 20110301331A1 · Glaser et al. · 2011 [cited by applicant]
US 20120065379A1 · Igawa et al. · 2012 [cited by applicant]
US 20120071634A1 · Igawa et al. · 2012 [cited by applicant]
US 20120149876A1 · Von Kreudenstein et al. · 2012 [cited by applicant]
US 20120244578A1 · Kannan et al. · 2012 [cited by applicant]
US 20140199294A1 · Mimoto et al. · 2014 [cited by applicant]
US 20150166636A1 · Igawa et al. · 2015 [cited by applicant]
US 20150166654A1 · Igawa et al. · 2015 [cited by applicant]
US 20150210763A1 · Kuramochi et al. · 2015 [cited by applicant]
US 20150274809A1 · Igawa et al. · 2015 [cited by applicant]
US 20150344570A1 · Igawa et al. · 2015 [cited by applicant]
US 20160159915A1 · Igawa et al. · 2016 [cited by applicant]
US 20160229915A1 · Igawa et al. · 2016 [cited by applicant]
US 20160304862A1 · Igawa et al. · 2016 [cited by applicant]
US 20170283483A1 · Igawa et al. · 2017 [cited by applicant]
US 20170342154A1 · Igawa et al. · 2017 [cited by applicant]
US 20170355756A1 · Julien · 2017 [cited by examiner]
US 20180051307A1 · Igawa et al. · 2018 [cited by applicant]
US 20180155451A1 · Mimoto et al. · 2018 [cited by applicant]
US 20180185481A1 · Van Dijk et al. · 2018 [cited by applicant]
US 20190085082A1 · Bicknell et al. · 2019 [cited by applicant]
US 20190211081A1 · Igawa et al. · 2019 [cited by applicant]
US 20190241662A1 · Luo et al. · 2019 [cited by applicant]
US 20190359704A1 · Igawa et al. · 2019 [cited by applicant]
US 20200181257A1 · Kuramochi et al. · 2020 [cited by applicant]
US 20210047410A1 · Liu et al. · 2021 [cited by applicant]
US 20210180049A1 · Igawa et al. · 2021 [cited by applicant]
US 20220064264A1 · Igawa et al. · 2022 [cited by applicant]
US 20220242934A1 · Igawa et al. · 2022 [cited by applicant]
US 20220251225A1 · Igawa et al. · 2022 [cited by applicant]
US 20220267822A1 · Igawa et al. · 2022 [cited by applicant]
US 20230058982A1 · Katada et al. · 2023 [cited by applicant]
US 20230220083A1 · Igawa et al. · 2023 [cited by applicant]
US 20230257470A1 · Igawa et al. · 2023 [cited by applicant]
US 20230279099A1 · Igawa et al. · 2023 [cited by applicant]
US 20240158785A1 · Igawa et al. · 2024 [cited by applicant]
CA 2565961A1 · 2006 [cited by applicant]
CA 2815266A1 · 2012 [cited by applicant]
CA 2850035A1 · 2013 [cited by applicant]
CA 2931296A1 · 2015 [cited by applicant]
CN 1291198A · 2001 [cited by applicant]
CN 103827300A · 2014 [cited by applicant]
CN 104204204A · 2014 [cited by applicant]
CN 105102618A · 2015 [cited by applicant]
CN 105980557A · 2016 [cited by applicant]
CN 107207607A · 2017 [cited by applicant]
CN 105102618B · 2018 [cited by applicant]
CN 108473562A · 2018 [cited by applicant]
CN 109517059A · 2019 [cited by applicant]
CN 105980557B · 2020 [cited by applicant]
CN 112839960A · 2021 [cited by applicant]
CN 112996813A · 2021 [cited by applicant]
CN 108473562B · 2022 [cited by applicant]
CN 109517059B · 2023 [cited by applicant]
CN 117545779A · 2024 [cited by applicant]
CN 117616123A · 2024 [cited by applicant]
CN 112839960B · 2024 [cited by applicant]
CN 117616123B · 2024 [cited by applicant]
EP 1537878A1 · 2005 [cited by applicant]
EP 2196541A1 · 2010 [cited by applicant]
EP 2196541B1 · 2012 [cited by applicant]
EP 2728002A1 · 2014 [cited by applicant]
EP 2762493A1 · 2014 [cited by applicant]
EP 2857420A1 · 2015 [cited by applicant]
EP 2862875A1 · 2015 [cited by applicant]
EP 2940135A1 · 2015 [cited by applicant]
EP 3078744A1 · 2016 [cited by applicant]
EP 3586872A1 · 2020 [cited by applicant]
EP 2857420B1 · 2020 [cited by applicant]
EP 3738980A1 · 2020 [cited by applicant]
EP 2762493B1 · 2021 [cited by applicant]
EP 3835321A · 2021 [cited by applicant]
EP 4082570A1 · 2022 [cited by applicant]
EP 2862875B1 · 2023 [cited by applicant]
EP 4361176A1 · 2024 [cited by applicant]
EP 4361273A1 · 2024 [cited by applicant]
JP 2006524039A · 2006 [cited by applicant]
JP 2008505174A · 2008 [cited by applicant]
JP 2014504265A · 2014 [cited by applicant]
JP 2014509857A · 2014 [cited by applicant]
JP 2014528906A · 2014 [cited by applicant]
JP 5972915B2 · 2016 [cited by applicant]
JP 6167040B2 · 2017 [cited by applicant]
JP 6204350B2 · 2017 [cited by applicant]
JP 6433297B2 · 2018 [cited by applicant]
JP 2019503655A · 2019 [cited by applicant]
JP 2020040975A · 2020 [cited by applicant]
JP 2020073557A · 2020 [cited by applicant]
JP 6768800B2 · 2020 [cited by applicant]
JP 2021511812A · 2021 [cited by applicant]
JP 6931034B2 · 2021 [cited by applicant]
JP 7012104B2 · 2022 [cited by applicant]
RU 2006142852A · 2008 [cited by applicant]
RU 2007107909A · 2008 [cited by applicant]
RU 2398777C2 · 2010 [cited by applicant]
TW 201116625A · 2011 [cited by applicant]
TW I507525B · 2015 [cited by applicant]
WO WO9940117A1 · 1999 [cited by applicant]
WO WO0037504A2 · 2000 [cited by applicant]
WO WO0042072A2 · 2000 [cited by applicant]
WO WO0114424A2 · 2001 [cited by applicant]
WO WO2004004771A1 · 2004 [cited by applicant]
WO WO2004063351A2 · 2004 [cited by applicant]
WO WO2004099249A2 · 2004 [cited by applicant]
WO WO2005003298A2 · 2005 [cited by applicant]
WO WO2006015371A2 · 2006 [cited by applicant]
WO WO2006019447A1 · 2006 [cited by applicant]
WO WO2006036291A2 · 2006 [cited by applicant]
WO WO2006085938A2 · 2006 [cited by applicant]
WO WO2006088494A2 · 2006 [cited by applicant]
WO WO2006106905A1 · 2006 [cited by applicant]
WO WO2006133486A1 · 2006 [cited by applicant]
WO WO2007024249A2 · 2007 [cited by applicant]
WO WO2007114325A1 · 2007 [cited by applicant]
WO WO2008068048A2 · 2008 [cited by examiner]
WO WO2009041062A1 · 2009 [cited by applicant]
WO WO2009041613A1 · 2009 [cited by applicant]
WO WO2009062083A2 · 2009 [cited by applicant]
WO WO2010085682A2 · 2010 [cited by applicant]
WO WO2010107109A1 · 2010 [cited by applicant]
WO WO2010107110A1 · 2010 [cited by applicant]
WO WO2011107989A1 · 2011 [cited by applicant]
WO WO2012032080A1 · 2012 [cited by applicant]
WO WO2012058768A1 · 2012 [cited by applicant]
WO WO2012120125A1 · 2012 [cited by applicant]
WO WO2012125850A1 · 2012 [cited by applicant]
WO WO2013002362A1 · 2013 [cited by applicant]
WO WO2013046704A2 · 2013 [cited by applicant]
WO WO2013047748A1 · 2013 [cited by applicant]
WO WO2013063702A1 · 2013 [cited by applicant]
WO WO2013118858A1 · 2013 [cited by applicant]
WO WO2013180200A1 · 2013 [cited by applicant]
WO WO2013187495A1 · 2013 [cited by applicant]
WO WO2014104165A1 · 2014 [cited by applicant]
WO WO2014177459A2 · 2014 [cited by applicant]
WO WO2015083764A1 · 2015 [cited by applicant]
WO WO2016098356A1 · 2016 [cited by applicant]
WO WO2016196237A1 · 2016 [cited by applicant]
WO WO2017087588A1 · 2017 [cited by applicant]
WO WO2017104783A1 · 2017 [cited by applicant]
WO WO2018146317A1 · 2018 [cited by applicant]
WO WO2018155611A1 · 2018 [cited by applicant]
WO WO2018223182A1 · 2018 [cited by applicant]
WO WO2019148444A1 · 2019 [cited by applicant]
WO WO2019152413A1 · 2019 [cited by applicant]
WO WO2020014413A2 · 2020 [cited by applicant]
WO WO2020092155A1 · 2020 [cited by applicant]
WO WO2021131021A1 · 2021 [cited by applicant]
WO WO2022044248A1 · 2022 [cited by applicant]
WO WO2022045276A1 · 2022 [cited by applicant]
WO WO2022270611A1 · 2022 [cited by applicant]
WO WO2022270612A1 · 2022 [cited by applicant]
Edwards et al., The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol. Nov. 14, 2003;334(1):103-18. (Year: 2003). [cited by examiner]
Chen et al., Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations. EMBO J. Jun. 15, 1995;14(12):2784-94. (Year: 1995). [cited by examiner]
Koenig et al., Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding. PNAS Jan. 24, 2017 114 (4) E486-E495; first published Jan. 5, 201… [cited by examiner]
Kussie, Paul H., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity”, 1994, Journal of Immunology 152(1): pp. 146-152. (Year: 1994). [cited by examiner]
Contardi et al. “CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction”. Int. J. Cancer: 117,pp. 538-550. (Year: 2005). [cited by examiner]
Bjellqvist, B., et al., “The Focusing Positions of Polypeptides in Immobilized pH Gradients Can Be Predicted From Their Amino Acid Sequences,” Electrophoresis, 14(10):1023-1031 (1993). [cited by applicant]
Brunet, J.F., et al., “A New Member of the Immunoglobulin Superfamily-CTLA-4,” Nature, 328(6127):267-270 (1987). [cited by applicant]
Cartron, G., et al., “Therapeutic Activity of Humanized Anti-cCD20 Monoclonal Antibody and Polymorphism in IgG Fc Receptor FcgammaRIIIa Gene,” Blood, 99(3):754-758 (2002). [cited by applicant]
Chen, X., et al., “FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy,” Front Immunol., 10:292 (2019). [cited by applicant]
Chu, S.Y., et al., “Inhibition of B Cell Receptor-Mediated Activation of Primary Human B Cells by Coengagement of CD19 and FcgammaRIIb With Fc-engineered Antibodies,” Molecular Immunology, 45(15):3926-3933 (2008). [cited by applicant]
Clark, R., “IgG Effector Mechanisms,” Chemical Immunology, 65:88-110 (1997). [cited by applicant]
Clynes, R., et al., “Fc Receptors Are Required in Passive and Active Immunity to Melanoma,” Proceedings of the National Academy of Sciences of the United States of America, 95(2):652-656 (1998). [cited by applicant]
Clynes, R.A., et al., “Inhibitory Fc Receptors Modulate in Vivo Cytotoxicity Against Tumor Targets,” Nature Medicine, 6(4):443-446 (2000). [cited by applicant]
Davis, J.H., et al., “SEEDbodies: Fusion Proteins Based on Strand-exchange Engineered Domain (SEED) C [cited by applicant]
Dondelinger, M., et al., “Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition,” Front Immunol., 9:2278 (2018). [cited by applicant]
Escobar-Cabrera, E., et al., “Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function,” Antibodies, 6:7 (2017). [cited by applicant]
Final Office Action dated Aug. 29, 2023 in U.S. Appl. No. 16/795,676, filed Feb. 20, 2020, Kuramochi et al. [cited by applicant]
Gonzales, N. R., et al., “Minimizing the Immunogenicity of Antibodies for Clinical Application,” Tumor Biol., 26(1):31-43 (2005). [cited by applicant]
Greenwood, J., et al., “Structural Motifs Involved in Human IgG Antibody Effector Functions,” European Journal of Immunology, 23(5):1098-1104 (1993). [cited by applicant]
Gunasekaran, K., et al., “Enhancing Antibody Fc Heterodimer Formation Through Electrostatic Steering Effects: Applications to Bispecific Molecules and Monovalent IgG,” The Journal of Biological Chemistry, 285(25):19637-… [cited by applicant]
Ha, D., et al., “Differential Control of Human Treg and Effector T Cells in Tumor Immunity by Fc-engineered Anti-CTLA-4 Antibody,” Proceedings of the National Academy of Sciences of the United States of America, 116(2):… [cited by applicant]
Horton, H.M., et al., “Potent in Vitro and in Vivo Activity of an Fc-engineered Anti-CD19 Monoclonal Antibody Against Lymphoma and Leukemia,” Cancer Research, 68(19):8049-8057 (2008). [cited by applicant]
Igawa, et al., “Antibody Optimization Technologies for Developing Next Generation Antibody Therapeutics”, Bio Industry, 28(7):15-21 (2011). [cited by applicant]
Jefferis, R., et al., “Interaction Sites on Human IgG-fc for FcgammaR: Current Models,” Immunology Letters, 82(1-2):57-65 (2002). [cited by applicant]
Kunik, V., et al., “Structural Consensus among Antibodies Defines the Antigen Binding Site,” PLoS Comput Biol., 8(2):e1002388 (2012). [cited by applicant]
Kussie, P. H., et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity,” J Immunol., 152:146-152 (1994). [cited by applicant]
Lazar, G.A., et al., “Engineered Antibody Fc Variants With Enhanced Effector Function,” Proceedings of the National Academy of Sciences of the United States of America, 103(11):4005-4010 (2006). [cited by applicant]
Leach, D.R., et al., “Enhancement of Antitumor Immunity by CTLA-4 blockade,” Science, 271(5256):1734-1736 (1996). [cited by applicant]
Liu, Z., et al., “Fine mapping of the antigen-antibody interaction of scFv215, a recombinant antibody inhibiting RNA polymerase II from [cited by applicant]
Liu, Z., et al., “Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies,” J Biol Chem., 289(6):3571-3590 (2014). [cited by applicant]
Marvin, J.S., et al., “Recombinant Approaches to Igg-like Bispecific Antibodies,” Acta Pharmacologica Sinica, 26(6):649-658 (2005). [cited by applicant]
Meulenbroek, A.J. and Zeijlemaker, W. P., “Human IgG Subclasses: Useful diagnostic markers for Immunocompetence, 2.3 Properties of human IgG subclasses,” Sanquin formerly CLB (Centraal Laboratorium van de Bloedtransfusi… [cited by applicant]
Mimoto, F., et al., “Engineered Antibody Fc Variant With Selectively Enhanced FcγRIIb Binding Over Both FcγRIIa(R131) and FcγRIIa(H131),” Protein Engineering, Design & Selection, 26(10):589-598 (2013). [cited by applicant]
Mimoto, F., et al., “Crystal Structure of a Novel Asymmetrically Engineered Fc Variant with Improved Affinity for FcγRs,” Molecular Immunology, 58(1):132-138 (2014). [cited by applicant]
Morgan, A., et al., “The N-Terminal End of the CH2 Domain of Chimeric Human IgG1 Anti-HLA-DR is Necessary for C1q, Fc Gamma RI and Fc Gamma RIII Binding,” Immunology, 86(2):319-324 (1995). [cited by applicant]
Nezu, J., et al., “Chugai's Strategy for Drug Discovery Research,” Chugai Pharmaceutical Co., Ltd. Presentation Dec. 9, 2019, pp. 1-80. [cited by applicant]
Nimmerjahn, F., et al., “Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding,” Science, 310(5753):1510-1512 (2005). [cited by applicant]
Nishikawa, H., et al., “Regulatory T cells in Tumor Immunity,” International Journal of Cancer, 127(4):759-767 (2010). [cited by applicant]
Office Action dated Jan. 31, 2023 in U.S. Appl. No. 16/795,676, filed Feb. 20, 2020, Kuramochi et al. [cited by applicant]
Okabe, H., “Proprietary Innovative Antibody Engineering Technologies in Chugai Pharmaceutical,” Information Meeting on Antibody Engineering Technologies, pp. 78 (2012). [cited by applicant]
Panka, D. J., et al., “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies,” Proc Natl Acad Sci., 85:3080-3084 (1988). [cited by applicant]
Pardoll, D.M., et al., “The Blockade of Immune Checkpoints in Cancer Immunotherapy,” Nature Reviews. Cancer, 12(4):252-264 (2012). [cited by applicant]
Pavlou, A.K. and Belsey, M.J, “The Therapeutic Antibodies Market to 2008,” European Journal of Pharmaceutics and Biopharmaceutics, 59(3):389-396 (2005). [cited by applicant]
Radaev, S., et al., “The Structure of a Human Type III Fcgamma Receptor in Complex With Fc,” The Journal of Biological Chemistry, 276(19):16469-16477 (2001). [cited by applicant]
Ramagopal, U. A., et al., “Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab,” PNAS, 114(21):E4223-E4232 (2017). [cited by applicant]
Reichert, J.M., et al., “Monoclonal Antibody Successes in the Clinic,” Nature Biotechnology, 23(9):1073-1078 (2005). [cited by applicant]
Restriction Requirement dated Jul. 21, 2022, in U.S. Appl. No. 16/795,676, filed Feb. 20, 2020, Kuramochi et al. [cited by applicant]
Richards, J.O., et al., “Optimization of Antibody Binding to FcgammaRIIa Enhances Macrophage Phagocytosis of Tumor Cells,” Molecular Cancer Therapeutics, 7(8):2517-2527 (2008). [cited by applicant]
Ridgway, J.B., et al., “Knobs-into-holes' Engineering of Antibody CH3 Domains for Heavy Chain Heterodimerization,” Protein Engineering, 9(7):617-621 (1996). [cited by applicant]
Sakaguchi, S., et al., “Immunologic Self-tolerance Maintained by Activated T cells Expressing IL-2 Receptor Alpha-chains (CD25). Breakdown of a Single Mechanism of Self-Tolerance Causes Various Autoimmune Diseases,” Jou… [cited by applicant]
Samuelsson, A., et al., “Anti-Inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor,” Science, 291(5503):484-486 (2001). [cited by applicant]
Sela-Culang, I., et al., “The structural basis of antibody-antigen recognition,” Front Immunol. 4:302 (2013). [cited by applicant]
Shields, R. L., et al., “High Resolution Mapping of the Binding Site on Human IgG1 for Fc Gamma RI, Fc Gamma RIII, Fc Gamma RIII, and FcRn and Design of Igg1 Variants With Improved Binding to the Fc Gamma R,” The Journa… [cited by applicant]
Shinkawa, T., et al., “The Absence of Fucose but Not the Presence of Galactose or Bisecting N-acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellula… [cited by applicant]
Takahashi, T., et al., “Immunologic Self-tolerance Maintained by CD25(+)CD4(+) Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte-associated Antigen 4,” The Journal of Experimental Medicine, 192(2):303-… [cited by applicant]
Tamura, K., et al., “FcγR2A and 3A Polymorphisms Predict Clinical Outcome of Trastuzumab in Both Neoadjuvant and Metastatic Settings in Patients with HER2-positive Breast Cancer,” Annals of Oncology, 22(6):1302-1307 (20… [cited by applicant]
Tsao, et al., “CD47 Blockade Augmentation of Trastuzumab Antitumor Efficacy Dependent on Antibody-dependent Cellular Phagocytosis,” JCI Insight, 4(24):e131882 (2019). [cited by applicant]
Wark, K. L. and Hudson, P. J., “Latest technologies for the enhancement of antibody affinity,” Adv Drug Del Rev., 58(5-6):657-670 (2006). [cited by applicant]
Warncke, M., et al., “Different Adaptations of IgG Effector Function in Human and Nonhuman Primates and Implications for Therapeutic Antibody Treatment,” Journal of Immunology, 188(9):4405-4411 (2012). [cited by applicant]
Wong, Y. W., et al., “Structural Requirements for a Specificity Switch and for Maintenance of Affinity Using Mutational Analysis of a Phage-Displayed Anti-Arsonate Antibody of Fab Heavy Chain First Complementarity-Deter… [cited by applicant]
Wu, H., et al., “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues,” J Mol Biol., 294:151-162 (1999). [cited by applicant]
Zalevsky, J., et al., “The Impact of Fc Engineering on an Anti-CD19 Antibody: Increased Fcgamma Receptor Affinity Enhances B-cell Clearing in Nonhuman Primates,” Blood, 113(16):3735-3743 (2009). [cited by applicant]
Zhang, P., et al., “Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies,” Cancers, 12(2):284 (2020). [cited by applicant]
U.S. Appl. No. 09/483,588, filed Jan. 14, 2000, Presta. [cited by applicant]
U.S. Appl. No. 09/520, 130, filed Mar. 7, 2000, Arathoon et al. [cited by applicant]
U.S. Appl. No. 11/124,620, filed May 5, 2005, Lazar et al. [cited by applicant]
U.S. Appl. No. 11/271,140, filed Nov. 10, 2005, Stavenhagen. [cited by applicant]
U.S. Appl. No. 11/433,313, filed May 11, 2006, Van Vlijmen et al. [cited by applicant]
U.S. Appl. No. 11/841,821, filed Aug. 20, 2007, Lazar et al. [cited by applicant]
U.S. Appl. No. 11/910,128, filed Oct. 7, 2008, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 12/295,075, filed Apr. 20, 2009, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 12/377,251, filed Jul. 7, 2010, Bernett et al. [cited by applicant]
U.S. Appl. No. 12/680,082, filed Jun. 25, 2010, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 12/811,207, filed Jun. 29, 2010, Kannan et al. [cited by applicant]
U.S. Appl. No. 12/823,838, filed Jun. 25, 2010, Davis et al. [cited by applicant]
U.S. Appl. No. 13/257,112, filed Nov. 22, 2011, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 13/257,145, filed Nov. 22, 2011, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 13/289,934, filed Nov. 4, 2011, Von Kreudenstein et al. [cited by applicant]
U.S. Appl. No. 13/511,133, filed May 21, 2012, Kannan et al. [cited by applicant]
U.S. Appl. No. 14/127,576, filed Mar. 13, 2014, Mimoto et al., related application. [cited by applicant]
U.S. Appl. No. 14/377,556, filed Aug. 8, 2014, Kuramochi et al., related application. [cited by applicant]
U.S. Appl. No. 14/402,574, filed Nov. 20, 2014, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 14/406,232, filed Dec. 8, 2014, Igawa et al. [cited by applicant]
U.S. Appl. No. 14/654,895, filed Jun. 23, 2015, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 14/680,250, filed Apr. 7, 2015, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 14/962,293, filed Dec. 8, 2015, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 15/024,063, filed Mar. 23, 2016, Igawa et al. [cited by applicant]
U.S. Appl. No. 15/100,934, filed Jun. 1, 2016, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 15/490,936, filed Apr. 19, 2017, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 15/614,842, filed Jun. 6, 2017, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 15/782,256, filed Oct. 12, 2017, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 15/860,163, filed Jan. 2, 2018, Mimoto et al., related application. [cited by applicant]
U.S. Appl. No. 16/298,032, filed Mar. 11, 2019, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 16/539,765, filed Aug. 13, 2019, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 16/795,676, filed Feb. 20, 2020, Kuramochi et al., related application. [cited by applicant]
U.S. Appl. No. 17/182,331, filed Feb. 23, 2021, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 17/520,368, filed Nov. 5, 2021, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 17/530,542, filed Nov. 19, 2021, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 17/720,937, filed Apr. 14, 2022, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 17/788,998, filed Jun. 24, 2022, Katada et al., related application. [cited by applicant]
U.S. Appl. No. 18/022,342, filed Feb. 21, 2023, Katada et al., related application. [cited by applicant]
U.S. Appl. No. 18/023,038, filed Feb. 24, 2023, Katada et al., related application. [cited by applicant]
U.S. Appl. No. 18/052,258, filed Nov. 3, 2022, Igawa et al. [cited by applicant]
U.S. Appl. No. 18/138,888, filed Apr. 25, 2023, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 18/176,201, filed Feb. 28, 2023, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 18/298,743, filed Apr. 11, 2023, Igawa et al. [cited by applicant]
U.S. Appl. No. 18/411,929, filed Jan. 12, 2024, Igawa et al., related application. [cited by applicant]
U.S. Appl. No. 11/910,128, filed Oct. 7, 2008, Igawa et al. [cited by applicant]
U.S. Appl. No. 12/295,075, filed Apr. 20, 2009, Igawa et al. [cited by applicant]
U.S. Appl. No. 12/680,082, filed Jun. 25, 2010, Igawa et al. [cited by applicant]
U.S. Appl. No. 13/257,112, filed Nov. 22, 2011, Igawa et al. [cited by applicant]
U.S. Appl. No. 13/257,145, filed Nov. 22, 2011, Igawa et al. [cited by applicant]
U.S. Appl. No. 14/127,576, filed Mar. 13, 2014, Mimoto et al. [cited by applicant]
U.S. Appl. No. 14/377,556, filed Aug. 8, 2014, Kuramochi et al. [cited by applicant]
U.S. Appl. No. 14/402,574, filed Nov. 20, 2014, Igawa et al. [cited by applicant]
U.S. Appl. No. 14/654,895, filed Jun. 23, 2015, Igawa et al. [cited by applicant]
U.S. Appl. No. 14/680,250, filed Apr. 7, 2015, Igawa et al. [cited by applicant]
U.S. Appl. No. 14/962,293, filed Dec. 8, 2015, Igawa et al. [cited by applicant]
U.S. Appl. No. 15/100,934, filed Jun. 1, 2016, Igawa et al. [cited by applicant]
U.S. Appl. No. 15/490,936, filed Apr. 19, 2017, Igawa et al. [cited by applicant]
U.S. Appl. No. 15/614,842, filed Jun. 6, 2017, Igawa et al. [cited by applicant]
U.S. Appl. No. 15/782,256, filed Oct. 12, 2017, Igawa et al. [cited by applicant]
U.S. Appl. No. 15/860,163, filed Jan. 2, 2018, Mimoto et al. [cited by applicant]
U.S. Appl. No. 16/298,032, filed Mar. 11, 2019, Igawa et al. [cited by applicant]
U.S. Appl. No. 16/539,765, filed Aug. 13, 2019, Igawa et al. [cited by applicant]
U.S. Appl. No. 16/795,676, filed Feb. 20, 2020, Kuramochi et al. [cited by applicant]
U.S. Appl. No. 17/182,331, filed Feb. 23, 2021, Igawa et al. [cited by applicant]
U.S. Appl. No. 17/520,368, filed Nov. 5, 2021, Igawa et al. [cited by applicant]
U.S. Appl. No. 17/530,542, filed Nov. 19, 2021, Igawa et al. [cited by applicant]
U.S. Appl. No. 17/720,937, filed Apr. 14, 2022, Igawa et al. [cited by applicant]
U.S. Appl. No. 17/788,998, filed Jun. 24, 2022, Katada et al. [cited by applicant]
U.S. Appl. No. 18/022,342, filed Feb. 21, 2023, Katada et al. [cited by applicant]
U.S. Appl. No. 18/023,038, filed Feb. 24, 2023, Katada et al. [cited by applicant]
U.S. Appl. No. 18/138,888, filed Apr. 25, 2023, Igawa et al. [cited by applicant]
U.S. Appl. No. 18/176,201, filed Feb. 28, 2023, Igawa et al. [cited by applicant]
U.S. Appl. No. 18/411,929, filed Jan. 12, 2024, Igawa et al. [cited by applicant]
Blanco, B., et al., “T Cell-Redirecting Strategies to ‘STAb’ Tumors: Beyond CARs and Bispecific Antibodies,” Trends Immunol., 40(3):243-257 (2019). [cited by applicant]
Chen, J., et al., “Advance in Research on Antibody Half-Life Related Engineering,” China Biotechnology, 37(5):87-96, with English abstract (2017). [cited by applicant]
Information Meeting on Antibody Engineering Technologies, Chugai Pharmaceutical Co., Ltd., Dec. 18, 2012. [cited by applicant]
Mimoto, F., et al., “Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant,” mAbs, 5(2):229-236 (2013). [cited by applicant]
Office Action dated May 8, 2024 in U.S. Appl. No. 16/795,676, filed Feb. 20, 2020, Kuramochi et al. [cited by applicant]
Pan, Y.-G., et al., “Research and application progress in intracellular single domain antibodies,” Practical Pharmacy and Clinical Remedies, 4:457-463, with English abstract (2018). [cited by applicant]
Rudikoff, S., et al. “Single amino acid substitution altering antigen-binding specificity,” Proc Natl Acad Sci 79:1979-1983 (1982). [cited by applicant]
Wang, X., et al., “IgG Fc engineering to modulate antibody effector functions,” Protein Cell, 9(1):63-73 (2018). [cited by applicant]
Yang, C., et al., “Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics,” Front Immunol., 8:1860 (2018). [cited by applicant]
Zhu, L., et al., “Study on the influence of CTLA4-Ig fusion protein glycosylation modification on its function,” Chinese Journal of Pharmaceutical Analysis, 40(8):1391-1398, with English abstract (2020). [cited by applicant]
Ohta, A., “A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment,” Front Immunol., 7:109 (2016). [cited by applicant]
U.S. Appl. No. 17/484,003, filed Sep. 24, 2021, Igawa et al. [cited by applicant]